Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

Tian Zhang, MD
Published: Thursday, Jan 25, 2018



Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

The phase III KEYNOTE-564 trial is evaluating pembrolizumab (Keytruda) in the adjuvant setting (NCT03142334). This study is assessing disease-free survival in high-risk patients with kidney cancer post-nephrectomy and is currently enrolling.

Sunitinib (Sutent) was approved by the FDA in November 2017 for the adjuvant treatment of patients with kidney cancer who have received nephrectomy and are at a high risk of recurrence. The agent was shown to delay disease recurrence, but it does not improve overall survival, Zhang explains.

There has been debate about whether the approval of sunitinib will lead to delays in accrual for these adjuvant trials. Zhang hopes that enrollment for KEYNOTE-564 will not be delayed by this approval of sunitinib, but considering the controversy around the benefit and toxicities, it may not affect the trial.


Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

The phase III KEYNOTE-564 trial is evaluating pembrolizumab (Keytruda) in the adjuvant setting (NCT03142334). This study is assessing disease-free survival in high-risk patients with kidney cancer post-nephrectomy and is currently enrolling.

Sunitinib (Sutent) was approved by the FDA in November 2017 for the adjuvant treatment of patients with kidney cancer who have received nephrectomy and are at a high risk of recurrence. The agent was shown to delay disease recurrence, but it does not improve overall survival, Zhang explains.

There has been debate about whether the approval of sunitinib will lead to delays in accrual for these adjuvant trials. Zhang hopes that enrollment for KEYNOTE-564 will not be delayed by this approval of sunitinib, but considering the controversy around the benefit and toxicities, it may not affect the trial.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x